老年女性乳腺癌患者新辅助内分泌治疗的近期疗效分析  

The Effects of Neoadjuvant Endocrine Therapy in Older Women with Breast Cancer

作　　者：何跃君[1] 刘自力[1] 王建[1] 唐金海[2] 

机构地区：[1]徐州医学院第二附属医院普外科,江苏徐州221006 [2]江苏省肿瘤医院乳腺外科,江苏南京210009

出　　处：《中国现代医生》2011年第25期157-158,共2页China Modern Doctor

摘　　要：目的探讨老年女性乳腺癌患者对新辅助内分泌治疗的反应，并分析其与临床病理参数之间的关系。方法筛选我院2006～2010年的854例乳腺癌中不能或不愿接受化疗的42例绝经后、ER阳性的乳腺癌患者，给予来曲唑治疗6个月。结果总有效率（CR＋PR）为61．9％，完全缓解（CR）3例，部分缓解（PR）23例，无变化（SD）10例，进展（PD）6例；ER（＋＋～＋＋＋）患者的有效率为77．3％（17／22），ER（＋）患者的有效率为45．0％，差异有显著性（x。=4．627，P=0．031）；为期治疗6个月的有效率高于为期3个月治疗的疗效（有效率分别为66．7％和38．1％），有显著性差异（x‘：6．873，P=0．009）；未发现新辅助内分泌治疗的反应与其他临床病理参数之间存在关联。结论绝经后ER阳性的乳腺癌患者采用来曲唑进行新辅助内分泌治疗是安全有效的，其疗效与受体状态以及治疗时间有关。Objective To investigate the efficacy of neoadjuvant endocrine therapy in treating older women with breast cancer and the correlation to clinicopathologic factors. Methods Forty-two cases of postmenopausal breast cancer with ER positive were treated with letrozole for 6 months. Results The total effective rate （CR＋PR）was 61.9%, complete remission achieved in 3 cases, partial remission in 23 cases,stable disease in 10 cases,progressive disease in 6 cases. Patients with ER （ ＋＋ - ＋＋＋ ） showed a significantly 2 higher effective rate than those with ER （ ＋ ） （ 77.3% and 45.0% respectively, ~ =4.627, P=O.031）; 6-month period of treatment 2 showed a significantly higher effective rate than a period of 3 months of treatment （ 66.7% and 38.1%, ~ =6.873, P=0.009 ） .We found no relationships between the response of neoadjuvant endocrine therapy and other clinicopathological parameters. Conclusion Letrozole is safe and effective to postmenopausal breast cancer patients,its efficacy is related to receptor status and period of treatment.

关 键 词：乳腺癌 新辅助内分泌治疗 来曲唑 

分 类 号：R737.9[医药卫生—肿瘤]